How I Treat Neuroendocrine Tumors

Neuroendocrine tumors (NETs) originate from diffuse neuroendocrine cell system and can develop in many organs. Gastroenteropancreatic (GEP) NETs account for approximately 70%, followed by bronchopulmonary thymic NETs.[1] The World Health Organization (WHO) classification divides GEP into well-differentiated poorly differentiated carcinoma (NEC). Well-differentiated be grade 1 (G1; mitotic count <2 per 10 HPF - high power field, Ki-67 < 3%), G2 (mitotic count: 2–20, Ki-67: 3–20%) tumors, G3 >20, > 20%).[2] Poorly NECs are always with >20 index >20% include small- large-cell NECs.[2] A total of to 13% do not have a primary site identified at the time diagnosis called unknown primary.[1] [3] also based on secretion vasoactive amines hormones functional (30%) nonfunctional (70%).[1] This article focuses management attention systemic therapy. Factors influencing initial medical decision-making NET status, stage, grade, burden metastatic disease, symptoms presentation.